Augmedix Q2 EPS $(0.12) Beats $(0.13) Estimate, Sales $10.78M Beat $10.41M Estimate
Portfolio Pulse from bharat@benzinga.com
Augmedix reported Q2 earnings per share (EPS) of $(0.12), beating the analyst consensus estimate of $(0.13) by 7.69%. This is a 40% increase over losses from the same period last year. The company also reported quarterly sales of $10.78 million, beating the analyst consensus estimate of $10.41 million by 3.55%. This is a 47.01% increase over sales from the same period last year.
August 07, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Augmedix's Q2 earnings and sales beat analyst estimates, showing significant YoY growth. This could positively impact the company's stock in the short term.
Augmedix's Q2 earnings and sales exceeded analyst estimates, which is typically a positive signal to investors and can lead to an increase in the stock price. The YoY growth in both earnings and sales also indicates that the company's financial performance is improving, which could further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100